AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

July 5, 2005

Primary Completion Date

March 14, 2008

Study Completion Date

March 14, 2008

Conditions
Pancreatic Neoplasms
Interventions
DRUG

Gemcitabine

Gemcitabine 1000 mg/m\^2 30 minutes IV infusion on Day 1, 8 and 15 of each cycle, in cycles of 4 weeks

DRUG

AG-013736

Axitinib (AG-013736) 5 mg tablet orally BID starting from Day 1 of Cycle 1, in cycles of 4 weeks.

DRUG

Gemcitabine

Gemcitabine 1000 mg/m\^2 30 minutes IV infusion on Day 1, 8 and 15 of each cycle, in cycles of 4 weeks.

Trial Locations (38)

9000

Universitair Ziekenhuis Gent/Dienst Gastroenterologie, Ghent

13005

Hopital La Timone, Marseille

13353

Medizinische Klinik mit Schwerpunkt Haematologie und Onkologie, Charité-Universitaetsmedizin Berlin, Berlin

20133

Fondazione IRCCS, Istituto Nazionale Tumori, Oncologia Medica B, Milan

27103

Piedmont Hematology Oncology Association, Winston-Salem

27292

Piedmont Hematology Oncology Associates, Winston-Salem

31052

Institut Claudius Regaud, Toulouse

33136

Jackson Memorial Hospital & Clinics, Miami

University of Miami Hospital & clinics, Miami

41013

Hospital Universitario Virgen Del Rocio, Seville

44805

Service Oncologie Medicale, Saint-Herblain

53792

University of Wisconsin Hospital and Clinics, Madison

63090

Arch Medical Services, Inc. d/b/a The Center for Cancer Care and Research, Washington

63141

Arch Medical Services, Inc. d/b/a The Center for Cancer Care and Research, St Louis

68510

Southeast Nebraska Cancer Center, Southeast Nebraska Hematology and Oncology Consultants, P.C., Lincoln

75651

Hopital de la Pitie Salpetriere, Paris

94509

East Bay Medical Oncology/Hematology Medical Associates Inc., Antioch

94520

Bay Area Cancer Research Group, Concord

East Bay Medical Oncology/Hematology Medical Associates, Inc., Concord

94704

Alta Bates Comprehensive Cancer Center, Berkeley

06902-3628

Hematology Oncology, P.C., Stamford

33612-9497

H Lee Moffitt Cancer Center & Research Institute, Tampa

04005

Maine Center for Cancer Medicine and Blood Disorders, Biddeford

04011

Maine Center for Cancer Medicine and Blood Disorders, Brunswick

04074

Maine Center for Cancer Medicine and Blood Disorders, Scarborough

T6G 1Z2

Cross Cancer Institute, Edmonton

R2H 2A6

Cancer Care Manitoba, Winnipeg

R3E 0V9

CancerCare Manitoba, Winnipeg

P6A 2C4

Sault Area Hospital, Sault Ste. Marie

M5G 2M9

Princess Margaret Hospital, Toronto

H2X 3J4

CHUM, Hopital Saint-Luc, Montreal

00168

Unita Operativa, Oncologia Medica, Istituto di Medicina Interna e Geriatria, Roma

08035

Hospital Universitario Vall D´Hebron, Barcelona

08036

Hospital Clinic I Provincial de Barcelona, Barcelona

SO16 6YD

Cancer Research Uk Clinical Centre, Southampton

LE1 5WW

Department of Cancer Studies & Molecular Medicine, Leicester

EH4 2XU

Western General Hospitals Nhs Trust, Edinburgh

W12 OHS

Hammersmith Hospital, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00219557 - AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter